Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$2.02 +0.50%

+$0.01 today

Market cap
$191.34M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.20M

Average 0.48M

CGEN Interest Expense

Cost of servicing the company's debt during the period.

Compugen Ltd.NASDAQ: CGEN

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Interest Expense vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Interest expense amounts to 0.0% of revenue for CGEN, versus a peer median of 15.8%.
CGEN Competitors
Interest Expense for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.04M USD+93.1%—394.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$2.04M USD-56.5%+39.2%64.3%
IPHAInnate Pharma S.A.FY2025€440K EUR-22.3%+15.2%15.8%
MOLNMolecular Partners AGLTM Mar 2026CHF 45.01K CHF+45.1%-69.7%—
CGENCompugen Ltd.LTM Mar 2026$0 USD——0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD-100.0%——
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$0 USD——0.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CGEN) —-22.3%+15.2%15.8%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$2.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.